Law Offices of Howard G. Smith announces that a new class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) securities between May 9, 2016 and July 7, 2016, inclusive (the “Class Period”). Juno investors have until September 12, 2016 to file a lead plaintiff motion.

Investors suffering losses on their Juno investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

The complaint filed in this lawsuit alleges that throughout the Class Period, defendants made misleading statements regarding the safety and efficacy of Juno’s JCAR015, specifically failing to disclose: (1) that in May 2016, a patient-participant in Juno’s Phase II clinical trial of JCAR015 died; (2) that this death called into question the efficacy and/or safety of JCAR015; (3) that, as a result, FDA approval of JCAR015 would be delayed and/or denied; and (4) that, as a result of the foregoing, Defendants’ statements about Juno’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Following the Company’s disclosure of the adverse events and the FDA’s clinical hold on JCAR015, Juno’s shares fell $13.01 per share, or 31.8%, to close at $27.81 per share on July 8, 2016, on unusually heavy trading volume.

If you purchased shares of Juno during the Class Period you may move the Court no later than September 12, 2016 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com

JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more JUNO THERAPEUTICS, INC. Charts.
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more JUNO THERAPEUTICS, INC. Charts.